0001919246-26-000014
SEC filingPelthos Therapeutics Inc. announced fourth quarter and full year 2025 financial results via press release, reporting ZELSUVMI net product revenue of $9.1 million in Q4 (28% increase from Q3) and $16.2 million since July 2025 launch, with total 2025 revenue of $16.8 million. Highlights include acquisitions of XEPI in November 2025 and XEGLYZE in January 2026, $18 million convertible notes financing, and $30 million term loan draw.